

ASX Release 13 November 2023

ASX code: PIQ

Proteomics International to present at the **Bell Potter Healthcare Conference**

Proteomics International Laboratories Ltd (Proteomics International, the Company; ASX: PIQ), is pleased to provide an opportunity for shareholders and investors to view a virtual presentation by Managing Director Dr Richard Lipscombe who will present at the Bell Potter Healthcare Conference 2023.

Event: Bell Potter Healthcare Conference

Date: Tuesday - Thursday, 14 - 16 November 2023

Format: Webinar

Register: Investors wishing to view the presentation must register before 5pm (EST), 13

November here:

https://extraconnect.co/bell-potter-healthcare-2023/

Authorised by Dr Richard Lipscombe (Managing Director) and Mr Neville Gardiner (Non-Executive Chairman) on behalf of the Board of PIQ.

ENDS

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr Richard Lipscombe Lisa Barnes **Managing Director Public Relations** Proteomics International Laboratories Ltd Profile Media T: +61 8 9389 1992 T: +61 416 583 672

E: enquiries@proteomicsinternational.com E: lisab@profilemedia.com.au

Dirk van Dissel **Kyle Moss**

Investor Relations & Corporate Advisor Corporate Advisor Candour Advisory **Euroz Hartleys** T: +61 408 326 367 T: +61 8 9488 1400

E: dirk@candouradvisory.com.au E: kmoss@eurozhartleys.com

Proteomics International Laboratories Ltd